GlassScriptPhysician profile
Anthony Handoyo
NPI 1922532795
$2,444.65
in general payments reported to CMS, 2019-2025
29 companies · $758 in 2025
The $758 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $109 · 2021: $84.89 · 2022: $257 · 2023: $610 · 2024: $625 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $349.43 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $271.12 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $235.35 | 2021-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $217.83 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $141.47 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $127.01 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.90 | 2024-2025 | |
| Dexcom, INC. | $112.08 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $109.39 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.29 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $63.30 | 2022-2023 | Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $61.36 | 2024-2025 | Breztri, Farxiga |
| Sumitomo Pharma America, INC. | $61.11 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $55.47 | 2023-2024 | Spravato, Xarelto |
| Sanofi Pasteur INC. | $48.94 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $45.26 | 2024 | |
| Amgen INC. | $45.17 | 2025 | Repatha, Otezla, Krystexxa |
| Sunovion Pharmaceuticals INC. | $44.43 | 2022 | |
| Merck Sharp & Dohme LLC | $43.21 | 2023-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Biogen, INC. | $37.48 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.21 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.11 | 2024 | Xifaxan |
| Seqirus USA INC | $22.45 | 2025 | Flucelvax, Fluad |
| Madrigal Pharmaceuticals | $19.86 | 2024 | Resmetirom |
| Otsuka America Pharmaceutical, INC. | $19.15 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $19.02 | 2024 | Unithroid |
| Inogen, INC. | $17.99 | 2025 | |
| Dynavax Technologies Corporation | $17.17 | 2022 | |
| Medtronic, INC. | $15.09 | 2024 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Handoyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.